CINXE.COM

<!DOCTYPE html><html lang="en" class="h-100"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title> UCSF Hodgkin's Lymphoma Trial → Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma</title><meta property="og:title" content="UCSF Hodgkin's Lymphoma Trial: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma"><meta name="description" content="This Hodgkin's Lymphoma and Lymphoma study at UCSF ends April 2025."><meta property="og:description" content="This Hodgkin's Lymphoma and Lymphoma study at UCSF ends April 2025."><meta property="og:url" content="https://clinicaltrials.ucsf.edu/trial/NCT03907488"><link rel="canonical" href="https://clinicaltrials.ucsf.edu/trial/NCT03907488"><meta name="author" content="UCSF"><meta name="generator" content="edu.ucsf.ctsi.rt.trialfinder"><meta name="referrer" content="origin-when-cross-origin"><meta name="google-site-verification" content="JXe923j97sTSgp-6yxsCdd25Muv0wMNfDR27ba3ER8M"><meta name="msvalidate.01" content="4E5209CC6688B86BBDD2FE074176C029"><link rel="shortcut icon" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/favicon.png"><link rel="alternate" type="application/atom+xml" title="UCSF Clinical Trials" href="https://clinicaltrials.ucsf.edu/meta/feed.atom"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ucsf"><meta property="og:image" content="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/share-image.jpg"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/ucsf_identity/banners.css"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/css/bootstrap.min.css" integrity="sha256-L/W5Wfqfa0sdBNIKN9cG6QA5F2qx4qICmU2VgLruv9Y=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/coliff/bootstrap-rfs@4.3.1/bootstrap-rfs.css" media="screen and (max-width: 1200px)" integrity="sha256-DgOE2c1ekD0TaTyiCQuH2NdeiZ6VifYJdLdfDwq6C+U=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/animate.css@3.7.2/animate.min.css" integrity="sha256-PHcOkPmOshsMBC+vtJdVr5Mwb7r0LkSVJPlPrp/IMpU=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/font-awesome@4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/css/style.css"><link rel="stylesheet" href="https://clinicaltrials.ucsf.edu/assets/local/ucsf/css/style-local.css"> <script src="https://polyfill-fastly.io/v3/polyfill.min.js?features=default%2CObject.assign%2CObject.entries%2CPromise%2CURLSearchParams%2CURL" crossorigin="anonymous" defer></script> <script src="https://cdn.jsdelivr.net/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-OUFW7hFO0/r5aEGTQOz9F/aXQOt+TwqI1Z4fbVvww04=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/readmore-js@2.2.1/readmore.min.js" integrity="sha256-ygz7RPJkJA9GMkV/1XKiK5GEfenXOdkEj2yhi8LRipU=" crossorigin="anonymous" defer></script> <script src="https://clinicaltrials.ucsf.edu/assets/js/app.js" defer></script><script>var google_analytics_live_mode=0;var google_analytics_id='UA-1142388-28';var google_analytics_hostname='clinicaltrials.ucsf.edu';if(google_analytics_id&&google_analytics_hostname&&window.location&&window.location.hostname&&window.location.hostname===google_analytics_hostname){google_analytics_live_mode=1}var google_analytics_js_url='https://www.google-analytics.com/analytics_debug.js';if(google_analytics_live_mode){google_analytics_js_url='https://www.google-analytics.com/analytics.js'}(function(c,h,e,b,f,a,d){c['GoogleAnalyticsObject']=f;c[f]=c[f]||function(){(c[f].q=c[f].q||[]).push(arguments)},c[f].l=1*new Date();a=h.createElement(e),d=h.getElementsByTagName(e)[0];a.async=1;a.src=b;d.parentNode.insertBefore(a,d)})(window,document,'script',google_analytics_js_url,'ga');if(!google_analytics_live_mode){}if(google_analytics_live_mode){ga('create',google_analytics_id,'auto')}else{ga('set','sendHitTask',null)}ga('require','outboundLinkTracker');ga('require','pageVisibilityTracker');ga('send','pageview');var s_opt={};s_opt['s_apid']='53G5XLK75T';s_opt['s_ixnm']='trials_ucsf';s_opt['s_ixky']='6e038166fd15da69c2ed075975c00816';s_opt['s_plac']=undefined;s_opt['s_mlti']=false;var _paq=window._paq=window._paq||[];_paq.push(['setTrackerUrl','https://clinicaltrials.ucsf.edu/action/t/l/']);_paq.push(['setSiteId','9']);_paq.push(['setCustomDimension',1,'trial\u002dpage']);_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);_paq.push(['enableHeartBeatTimer']);(function(){var a=document,g=a.createElement('script'),s=a.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.src='https://clinicaltrials.ucsf.edu/action/t/js/';s.parentNode.insertBefore(g,s)})();</script><script async src="https://cdn.jsdelivr.net/npm/autotrack@1.0.3/autotrack.js" integrity="sha256-MFv0PQKCj7HPlACiJTgQ+3rHnOSY1a510jcQGGwtemQ=" crossorigin="anonymous"></script><script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "WebSite", "publisher": { "@type": "MedicalOrganization", "name": "UCSF", "address": "San Francisco Bay Area", "url": "https://www.ucsf.edu/", "logo": "https://s2.googleusercontent.com/s2/favicons?domain_url=https%3A%2F%2Fwww.ucsf.edu%2F", "sameAs": [ "https://twitter.com/@ucsf" ] } } </script><meta name="ahrefs-site-verification" content="5f73483e1fea16c76799e8797bf1b843c1c0cda17921ee5e1670f98bd81223f4"></head><body class="trial-page bg-light d-flex flex-column"> <a id="skip-to-main-content" class="sr-only sr-only-focusable" href="#content">Skip to main content</a> <header id="header" class="mb-4"><div id="ucsf-banner-nav"><div class="container-fluid"><div class="top-header-container" style="max-width: 100%"><div><ul class="menu"><li class="first"><a href="https://www.ucsf.edu">University of California San Francisco</a></li><li><a href="https://www.ucsfhealth.org/">UCSF Medical Center</a></li><li><a href="https://www.ucsf.edu/search">Search UCSF</a></li><li><a href="https://www.ucsf.edu/about">About UCSF</a></li></ul></div></div></div></div><nav class="navbar navbar-expand-md navbar-light d-print"> <a class="navbar-brand" href="https://clinicaltrials.ucsf.edu/"> <img src="https://clinicaltrials.ucsf.edu/assets/local/ucsf/img/site-name.png" alt="UCSF Clinical Trials"> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbar--menu--primary-content" aria-controls="navbar--menu--primary-content" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-end" id="navbar--menu--primary-content"><ul class="navbar-nav"> <li class="nav-item" id="navbar--menu--home"> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/">Search</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/browse/" id="navbar--menu--browse-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Browse </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--browse-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/">All trials</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials for…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/healthy">Healthy volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/pediatric" title="Pediatric clinical trials, for people under age 18">People under 18</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/geriatric" title="Geriatric clinical trials, for people over age 65">People over 65</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials seeking…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/black" title="Trials that may be particularly relevant to Black volunteers"> Black volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/chinese" title="Trials that may be particularly relevant to Chinese volunteers"> Chinese volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/hmong" title="Trials that may be particularly relevant to Hmong volunteers"> Hmong volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/korean" title="Trials that may be particularly relevant to Korean volunteers"> Korean volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/latinx" title="Trials that may be particularly relevant to Latinx volunteers"> Latinx volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/lgbtqia" title="Trials that may be particularly relevant to LGBTQIA+ volunteers"> LGBTQIA+ volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/mena" title="Trials that may be particularly relevant to Middle Eastern or North African volunteers"> Middle Eastern or North African volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/native-hawaiian" title="Trials that may be particularly relevant to Native Hawaiian volunteers"> Native Hawaiian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/south-asian" title="Trials that may be particularly relevant to South Asian volunteers"> South Asian volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/veteran" title="Trials that may be particularly relevant to Veteran volunteers"> Veteran volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/browse/vietnamese" title="Trials that may be particularly relevant to Vietnamese volunteers"> Vietnamese volunteers</a> </div></li> <li class="nav-item" id="navbar--menu--equity" data-nosnippet> <a class="nav-link" href="https://clinicaltrials.ucsf.edu/about/equity">Equity <span class="d-none d-xl-inline">in Research</span></a></a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucsf.edu/about/" id="navbar--menu--about-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> About <span class="d-none d-lg-inline">the site</span> </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--about-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/">About UCSF Clinical Trials</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/for-researchers">For Researchers</a> <div class="dropdown-divider"></div><div class="dropdown-header">Learn more in…</div> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/chinese" data-nosnippet>Chinese</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/spanish" data-nosnippet>Spanish</a> <a class="dropdown-item" href="https://clinicaltrials.ucsf.edu/about/vietnamese" data-nosnippet>Vietnamese</a> </div></li></ul></div> </nav><nav class="breadcrumb-and-search-bar navbar navbar-expand navbar-light d-print d-flex justify-content-between"> <div><ol class="breadcrumb navbar-text my-0 pl-1" itemscope="itemscope" itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucsf.edu/" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" id="navbar--breadcrumb--link-1"> Home <meta itemprop="name" content="UCSF Clinical Trials"> </a> <meta itemprop="position" content="1"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucsf.edu/hodgkins-lymphoma" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" aria-description="See all trials related to Hodgkin's Lymphoma" id="navbar--breadcrumb--link-2"> <span itemprop="name">Hodgkin's Lymphoma</span> Studies </a> <meta itemprop="position" content="2"></li><li class="active">This trial</li></ol><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/hodgkins-lymphoma", "name": "Hodgkin's Lymphoma" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/lymphoma", "name": "Lymphoma" } }] } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{ "@type": "ListItem", "position": 1, "item": { "@id": "https://clinicaltrials.ucsf.edu/", "name": "UCSF Clinical Trials" } },{ "@type": "ListItem", "position": 2, "item": { "@id": "https://clinicaltrials.ucsf.edu/immunotherapy", "name": "Immunotherapy" } }] } </script></div> <div><div class="d-none d-md-block navbar-text"><form method="GET" action="https://clinicaltrials.ucsf.edu/" class="form-inline my-1" role="search"> <label class="sr-only" for="header-search--input">Search</label> <input id="header-search--input" name="q" type="text" class="form-control form-control-sm" placeholder="Search UCSF clinical trials" title="Search clinical trials at UCSF"> <input class="sr-only form-control-sm btn btn-sm btn-secondary" type="submit" value="Search trials"> </form></div></div> </nav></header><main id="content" class="mx-1 mx-md-0"> <div class="container-xl px-5"><div class="row"><div class="col-md-9 col-lg-8" role="main" id="main-column"><div id="summary" class="page-header show-jargon-definitions"><div class="h3 alert alert-danger text-center">This study is in progress, not accepting new patients</div><h1 id="summary--title"> Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma </h1><p class="h3 hide-long-content">a study on <span class="comma-list"><span class="comma-list-item"> <a href="../hodgkins-lymphoma">Hodgkin's Lymphoma</a></span><span class="comma-list-item"> <a href="../lymphoma">Lymphoma</a></span><span class="comma-list-item"> <a href="../immunotherapy">Immunotherapy</a></span></span></p></div><div id="trial-details-container"><div id="key-points" class="trial-details-block"><div class="row"> <div class="col"><h2 class="sr-only h3">Summary</h2><dl id="key-points-bullets" class="row"><dt class="d-none d-sm-block col-sm-1 col-lg-2"> <i class="fa fa-user fa-lg fa-fw" aria-hidden="true"></i> <span class="sr-only">Eligibility</span></dt><dd class="col-12 col-sm-11 col-lg-10"> <strong>for people ages 12 years and up</strong> (<a href="#eligibility">full criteria</a>) </dd><dt class="d-none d-sm-block col-sm-1 col-lg-2"> <i class="fa fa-map-marker fa-lg fa-fw" aria-hidden="true"></i> <span class="sr-only">Location</span></dt><dd class="col-12 col-sm-11 col-lg-10"> <a href="#location"> at San Francisco, California and other locations </a> </dd><dt class="d-none d-sm-block col-sm-1 col-lg-2"> <i class="fa fa-calendar fa-lg fa-fw" aria-hidden="true"></i> <span class="sr-only">Dates</span></dt><dd class="col-12 col-sm-11 col-lg-10"><div> study started <span itemscope itemtype="https://schema.org/WebPage"><time itemprop="dateCreated" datetime="2019-08-29">August 2019</time></span></div><div> completion around <time datetime="2025-04-01">April 2025</time></div><div itemscope itemtype="https://schema.org/WebPage" aria-hidden="true" class="d-none"><meta itemprop="datePublished" content="2019-04-09"></div></dd></dl></div> </div></div><div id="description" class="trial-details-block"><h2 class="h3">Description</h2><div class="show-jargon-definitions"><h3 class="h4">Summary</h3><div class="hide-long-content"><p>This phase III trial compares <a href="../immunotherapy" class="trial--link-to-condition-in-text">immunotherapy</a> drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV <a href="../hodgkins-lymphoma" class="trial--link-to-condition-in-text">classic Hodgkin lymphoma</a>. Immunotherapy with <a href="../monoclonal-antibody" class="trial--link-to-condition-in-text">monoclonal antibodies</a>, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.</p></div><h3 class="h4">Official Title</h3><p class="hide-long-content">A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age &gt;/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma</p><h3 class="h4">Details</h3><div class="hide-long-content"><p>PRIMARY OBJECTIVE:</p><ol type="a"><li>To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage <a href="../hodgkins-lymphoma" class="trial--link-to-condition-in-text">classical Hodgkin lymphoma</a> randomized to N-AVD (nivolumab, doxorubicin hydrochloride [doxorubicin], vinblastine sulfate [vinblastine], dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine).</li></ol><p>SECONDARY OBJECTIVES:</p><ol type="a"><li>To compare overall survival (OS) in patients randomized to N-AVD versus BV-AVD.</li></ol><p>II. To compare event-free survival (EFS) in patients randomized to N-AVD versus BV-AVD.</p><p>III. To compare the metabolic complete response (CR) rate at the end of treatment in patients randomized to N-AVD versus BV-AVD.</p><p>IV. To compare the physician-reported treatment-related adverse event rates between arms stratified by age groups.</p><ol type="a"><li>To compare patient-reported symptoms using selected Patient Reported Outcome Common Toxicity Criteria for Adverse Events (PRO-CTCAE) items between arms stratified by age groups.</li></ol><p>VI. To compare the safety and tolerability of N-AVD versus that of BV-AVD.</p><p>QUALITY OF LIFE OBJECTIVE:</p><ol type="a"><li>To compare between arms patient-reported fatigue, <a href="../neuropathy" class="trial--link-to-condition-in-text">neuropathy</a> and health-related quality of life over time (baseline, beginning of cycle 3, 4-8 weeks after the last dose of protocol therapy [following last dose of study drug or radiation therapy, whichever is later], and 1 and 3 years after randomization) using the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), and the PROMIS Global, respectively.</li></ol><p>BANKING OBJECTIVES:</p><ol type="a"><li>To bank specimens for future correlative studies. II. To bank positron emission tomography (PET)-computed tomography (CT) images for future correlative studies.</li></ol><p>OUTLINE: Patients are randomized to 1 of 2 arms.</p><p>ARM I: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim subcutaneously (SC) on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and/or magnetic resonance imaging (MRI) on study.</p><p>ARM II: Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.</p><p>After completion of study treatment and prior to disease progression, patients are followed up every 3 months for the first year, every 6 months for years 2 and 3, then annually until 10 years after registration. Patients are followed up at the time of progression and then annually until 10 years after registration. Patients who receive radiation therapy are followed up at 8-12 weeks after completion of radiation therapy.</p></div><h3 class="h4">Keywords</h3><p class=" hide-long-content"><span> Ann Arbor Stage III Hodgkin Lymphoma</span>, <span> Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma</span>, <span> <a href="../hodgkins-lymphoma" class="trial--link-to-condition-in-text">Ann Arbor Stage III Mixed Cellularity Classic</a> Hodgkin Lymphoma</span>, <span> Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma</span>, <span> Ann Arbor Stage IV Hodgkin Lymphoma</span>, <span> Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma</span>, <span> Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma</span>, <span> Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma</span>, <span> Classic Hodgkin Lymphoma</span>, <span> Lymphocyte-Rich Classic Hodgkin Lymphoma</span>, <span> Lymphoma</span>, <span> Hodgkin Disease</span>, <span> Sclerosis</span>, <span> Immunological Antineoplastic Agents</span>, <span> Nivolumab</span>, <span> Brentuximab Vedotin</span>, <span> Doxorubicin</span>, <span> Liposomal doxorubicin</span>, <span> Dacarbazine</span>, <span> Vinblastine</span>, <span> Antibodies</span>, <span> Immunoglobulins</span>, <span> <a href="../monoclonal-antibody" class="trial--link-to-condition-in-text">Monoclonal Antibodies</a></span>, <span> Lenograstim</span>, <span> Imidazole</span>, <span> Immunoconjugates</span>, <span> Biospecimen Collection</span>, <span> Computed Tomography</span>, <span> Doxorubicin Hydrochloride</span>, <span> Filgrastim</span>, <span> Magnetic Resonance Imaging</span>, <span> Pegfilgrastim</span>, <span> Positron Emission Tomography</span>, <span> Quality-of-Life Assessment</span>, <span> Radiation Therapy</span>, <span> Vinblastine Sulfate</span>, <span> chemotherapy, nivolumab, radiation</span>, <span> chemotherapy, brentuximab vedotin, radiation</span></p></div></div><div id="eligibility" class="trial-details-block show-jargon-definitions"><h2 class="h3">Eligibility</h2><div class="hide-long-content"><p><strong>For people ages 12 years and up</strong></p><p>Inclusion Criteria:</p><ul><li> All patients must have histologically confirmed newly diagnosed, previously untreated stage III or IV <a href="../hodgkins-lymphoma" class="trial--link-to-condition-in-text">classical Hodgkin lymphoma</a> (nodular sclerosing, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS]). Nodular lymphocyte predominant Hodgkin lymphoma is not eligible.</li><li> Patients must have bidimensionally measurable disease (at least one lesion with longest diameter >= 1.5 cm) documented on the Lymphoma Baseline Tumor Assessment Form in Rave.</li><li> Patients must have a whole body or limited whole body PET-CT scan performed within 42 days prior to registration. (A contrast-enhanced [diagnostic] CT, MRI or MR-PET is acceptable in event that PET-CT is contra-indicated, however if it is later possible to administer a PET-CT, then PET-CT is strongly preferred for the interim scan (after cycle 2) (if performed) and the EOT assessment. Otherwise, if PET-CT is not subsequently possible, then the same modality as baseline must be used throughout the trial.) NOTE: All images from PET-CT, CT, MRI or MR-PET scans performed as standard of care to assess disease (within 42 days prior to registration) must be submitted and associated radiology reports must be submitted.</li><li> Patients must be >= 12 years of age.</li><li> Patients must not have received any prior chemotherapy, radiation, or antibody-based treatment for classical Hodgkin lymphoma. Steroid pre-treatment is permitted.</li><li> Patients must not have had prior solid organ transplant.</li><li> Patients must not have had prior allogeneic stem cell transplantation.</li><li> Patients must not have received a live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette-Guerin [BCG], oral polio vaccine, and oral typhoid).</li><li> At registration, investigator must declare intent-to-treat with residual PET radiation therapy (residual PET RT- RPRT) to be administered after patient completes 6 cycles of therapy if, after end of treatment, the patient meets criteria specified for receiving RT). Patients will be stratified by investigator's intent-to-treat with residual PET RT. <ul><li> All pediatric patients (< 18 years of age) will be considered intent-to-treat with Residual PET RT at time of registration.</li></ul></li><li> Patients must have a performance status corresponding to Zubrod scores of 0, 1 or 2. Use Lansky for patients =< 17 years of age. *The conversion of the Lansky to Eastern Cooperative Oncology Group (ECOG) scales is intended for National Cancer Institute (NCI) reporting purposes only.</li><li> Adults (age 18 or older): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight.</li></ul><p>Pediatric Patients (age 12-17), the following must have been obtained within 14 days prior to registration:</p><ul><li> Measured or calculated creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m<sup>2</sup>, or</li><li> Serum creatinine =< 1.5 x institutional upper limit of normal (IULN), or a serum creatinine (SCr) based on age/gender as follows: <ul><li> Age < 13 maximum serum creatinine: Male 1.2 mg/dL; Female 1.2 mg/dL</li><li> Age 13 to < 16 maximum serum creatinine: Male 1.5 mg/dL; Female 1.4 mg/dL</li><li><p> Age 16-17 maximum serum creatinine: Male 1.7 mg/dL; Female 1.4 mg/dL</p><p>- Total bilirubin =< 2 x IULN (must be documented within 28 days prior to registration for adults [age 18 or older]; must be documented within 14 days prior to registration for pediatric patients [age 12-17]). </p></li></ul></li><li> Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome <ul><li> Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x IULN (must be documented within 28 days prior to registration for adults [age 18 or older]; must be documented within 14 days prior to registration for pediatric patients [age 12-17]).</li></ul></li><li> Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome <ul><li> Patients must have an echocardiogram (ECHO), multigated acquisition (MUGA), or functional cardiac imaging scan with a left ventricular ejection (LVEF) fraction >= 50% or a shortening fraction of >= 27%. For all patients, the ECHO, MUGA, or functional cardiac imaging scan must be performed within 42 days prior to registration.</li><li> Patients with known human immunodeficiency virus (HIV) infection must be receiving anti-retroviral therapy and have an undetectable or unquantifiable viral load at their most recent viral load test within 6 months prior to registration.</li><li> Patients must not have known active <a href="../hepatitis-b" class="trial--link-to-condition-in-text">hepatitis B</a> (HBV) or <a href="../hepatitis-c" class="trial--link-to-condition-in-text">hepatitis C virus</a> (HCV) at date of registration. Patients with previously treated HBV or HCV that have an undetectable viral load within 6 months prior to registration and no residual hepatic impairment are eligible.</li><li> Patients must not have any known central nervous system lymphoma.</li><li> Patients must not have a history of or active interstitial pneumonitis or <a href="../interstitial-lung-disease" class="trial--link-to-condition-in-text">interstitial lung disease</a>.</li><li> Patients must not have had a diagnosis of inherited or acquired immunodeficiency.</li><li> Patients must not have any known uncontrolled intercurrent illness including, but not limited to symptomatic <a href="../heart-failure" class="trial--link-to-condition-in-text">congestive heart failure</a>, unstable angina pectoris, hemodynamically unstable <a href="../cardiac-arrhythmia" class="trial--link-to-condition-in-text">cardiac arrhythmia</a>, or psychiatric illness/social situations that would limit compliance with study requirements.</li><li> Patients must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued prior to cycle 1, day 1.</li><li> Patients with <a href="../peripheral-neuropathy" class="trial--link-to-condition-in-text">peripheral neuropathy</a> must have < grade 2 at date of registration.</li><li> Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, immunosuppressive drugs, or corticosteroids with doses higher than prednisone 10 mg or equivalent). <a href="../autoimmune-disease" class="trial--link-to-condition-in-text">Autoimmune diseases</a> include but are not limited to <a href="../autoimmune-hepatitis" class="trial--link-to-condition-in-text">autoimmune hepatitis</a>, <a href="../inflammatory-bowel-disease" class="trial--link-to-condition-in-text">inflammatory bowel disease</a> (including <a href="../ulcerative-colitis" class="trial--link-to-condition-in-text">ulcerative colitis</a> and Crohn's disease), as well as symptomatic disease (e.g.: <a href="../rheumatoid-arthritis" class="trial--link-to-condition-in-text">rheumatoid arthritis</a>, systemic progressive sclerosis [scleroderma], <a href="../lupus" class="trial--link-to-condition-in-text">systemic lupus erythematosus</a>, autoimmune <a href="../vasculitis" class="trial--link-to-condition-in-text">vasculitis</a> [e.g., Wegener's granulomatosis]); central nervous system (CNS) or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and <a href="../myasthenia-gravis" class="trial--link-to-condition-in-text">myasthenia gravis</a>, <a href="../multiple-sclerosis" class="trial--link-to-condition-in-text">multiple sclerosis</a> or glomerulonephritis). Vitiligo, <a href="../alopecia" class="trial--link-to-condition-in-text">alopecia</a>, <a href="../hypothyroidism" class="trial--link-to-condition-in-text">hypothyroidism</a> on stable doses of thyroid replacement therapy, <a href="../psoriasis" class="trial--link-to-condition-in-text">psoriasis</a> not requiring systemic therapy within the past 2 years are permitted.</li><li> No second prior malignancy is allowed except for adequately treated basal (or squamous cell) <a href="../skin-cancer-melanoma" class="trial--link-to-condition-in-text">skin cancer</a>, any in situ cancer or other cancer for which the patient has been disease free for two years.</li><li> Females of childbearing potential must not be pregnant or nursing, and have a negative <a href="../pregnancy" class="trial--link-to-condition-in-text">pregnancy</a> test within 28 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method while receiving study drug and for women until 6 months after receiving the last dose of study drug or, for men, until 7 months after receiving the last dose of study drug. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral <a href="../oophorectomy" class="trial--link-to-condition-in-text">oophorectomy</a> or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.</li><li> Patients must have one formalin-fixed paraffin embedded (FFPE) diagnostic tumor block or at least 1 diagnostic, 4-5 micron, hematoxylin and eosin (H&E) slide collected prior to registration and available for submission.</li><li> Patients must be offered participation in banking for planned translational medicine and future research. With patient consent, any residuals from the mandatory tissue submission will also be banked for future research.</li><li> Patients who can complete Patient-Reported Outcome instruments in English, Spanish, or French must complete the PROMIS Fatigue, the FACT/GOG-Ntx, and the PROMIS Global prior to registration. Patients who do not complete PRO instruments prior to registration but are otherwise eligible will remain eligible for the primary analysis and other secondary analyses.</li><li> Patients who can complete Patient-Reported Outcome instruments in English, Spanish, or French must also agree to complete the PROMIS Fatigue, the FACT/GOG-Ntx, the PROMIS Global, and the PRO-CTCAE (or Pediatric [Ped] PRO-CTCAE) at the scheduled on-study assessment timepoints.</li><li> Patients must be informed of the investigational nature of this study and all patients and/or their parents or legal guardians (for patients < 18 years of age) must sign and give informed consent and assent (where appropriate) in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board Initiative (CIRB) regulations.</li></ul></li><li> Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.</li></ul></div></div><div id="location" class="trial-details-block"><h2 class="h3">Locations</h2><ul id="locations-list" class="hide-long-content "><li class="location location-is-institutional" itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">UCSF Medical Center-Mission Bay</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> San Francisco</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94158</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser Permanente-San Francisco</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> San Francisco</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94115</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser Permanente-Fresno</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> Fresno</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 93720</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser Permanente-South San Francisco</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> South San Francisco</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94080</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser Permanente-Richmond</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> Richmond</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94801</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser Permanente-Oakland</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> Oakland</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94611</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Valley Children's Hospital</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> Madera</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 93636</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser Permanente San Leandro</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> San Leandro</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94577</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser San Rafael-Gallinas</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> San Rafael</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94903</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li><li class="location " itemprop="address" itemscope itemtype="https://schema.org/PostalAddress"><span class="location-name" itemprop="name">Kaiser Permanente-Walnut Creek</span><br><span class="location-address comma-list comma-list--without-and"><span class="comma-list-item" itemprop="addressLocality"> Walnut Creek</span><span class="comma-list-item" itemprop="addressRegion"> California</span><span class="comma-list-item" itemprop="postalCode"> 94596</span><span class="comma-list-item" itemprop="addressCountry"> United States</span></span></li></ul></div><div id="details" class="trial-details-block"><h2 class="h3">Details</h2><dl class="row"><dt class="col-sm-3 text-sm-right">Status</dt><dd class="col-sm-9"> in progress, not accepting new patients </dd><dt class="col-sm-3 text-sm-right">Start Date</dt><dd class="col-sm-9"><time datetime="2019-08-29">August 2019</time></dd><dt class="col-sm-3 text-sm-right">Completion Date</dt><dd class="col-sm-9"><time datetime="2025-04-01">April 2025</time> (estimated)</dd><dt class="col-sm-3 text-sm-right">Sponsor</dt><dd class="col-sm-9">National Cancer Institute (NCI)</dd><dt class="col-sm-3 text-sm-right">ID</dt><dd class="col-sm-9"> <a href="https://clinicaltrials.gov/ct2/show/NCT03907488" class="trial--link-to-clinicaltrials-gov" target="_blank" rel="noopener nofollow" title="ClinicalTrials.gov identifier">NCT03907488</a> </dd><dt class="col-sm-3 text-sm-right">Phase</dt><dd class="col-sm-9">Phase 3 research study</dd><dt class="col-sm-3 text-sm-right">Study Type</dt><dd class="col-sm-9">Interventional</dd><dt class="col-sm-3 text-sm-right">Participants</dt><dd class="col-sm-9">About 995 people participating</dd><dt class="col-sm-3 text-sm-right">Last Updated</dt><dd class="col-sm-9"><span itemscope itemtype="https://schema.org/WebPage"><time itemprop="dateModified" datetime="2024-11-09">November 9, 2024</time></span></dd></dl></div><div id="faq" class="trial-details-block d-print-none" role="complementary"><h2 class="h3">Frequently Asked Questions</h2><ul><li><a href="../about/how-clinical-trials-work">How Do Clinical Trials Work?</a></li><li><a href="../about/what-to-expect">What to Expect</a></li><li><a href="../about/who-can-join">Who Can Join</a></li><li><a href="../about/our-researchers">Our Researchers</a></li></ul></div></div> </div><div class="col-md-3 text-center offset-lg-1 d-none d-md-block d-print-none" id="secondary-column"> <div id="sidebar"></div> </div></div> </div> <script type="application/ld+json"> [{"@context":"https://schema.org/","@type":"MedicalTrial","additionalType":"Product","alternateName":"A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma","code":{"@type":"MedicalCode","codeValue":"NCT03907488","codingSystem":"ClinicalTrials.gov"},"description":"This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.","healthCondition":[{"@type":"MedicalCondition","name":"Hodgkin's Lymphoma"},{"@type":"MedicalCondition","name":"Lymphoma"},{"@type":"MedicalCondition","name":"Immunotherapy"}],"name":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","sameAs":"https://clinicaltrials.gov/study/NCT03907488","sponsor":[{"@type":"Organization","name":"National Cancer Institute (NCI)"}],"status":"https://schema.org/ActiveNotRecruiting","studyLocation":[{"@type":"AdministrativeArea","address":{"@type":"PostalAddress","addressCountry":"United States","addressLocality":"San Francisco","addressRegion":"California","postalCode":"94158"},"name":"UCSF Medical Center-Mission Bay"}],"studySubject":[{"@type":"MedicalEntity","name":"Ann Arbor Stage III Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Ann Arbor Stage IV Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Lymphocyte-Rich Classic Hodgkin Lymphoma"},{"@type":"MedicalEntity","name":"Lymphoma"},{"@type":"MedicalEntity","name":"Hodgkin Disease"},{"@type":"MedicalEntity","name":"Sclerosis"},{"@type":"MedicalEntity","name":"Immunological Antineoplastic Agents"},{"@type":"MedicalEntity","name":"Nivolumab"},{"@type":"MedicalEntity","name":"Brentuximab Vedotin"},{"@type":"MedicalEntity","name":"Doxorubicin"},{"@type":"MedicalEntity","name":"Liposomal doxorubicin"},{"@type":"MedicalEntity","name":"Dacarbazine"},{"@type":"MedicalEntity","name":"Vinblastine"},{"@type":"MedicalEntity","name":"Antibodies"},{"@type":"MedicalEntity","name":"Immunoglobulins"},{"@type":"MedicalEntity","name":"Monoclonal Antibodies"},{"@type":"MedicalEntity","name":"Lenograstim"},{"@type":"MedicalEntity","name":"Imidazole"},{"@type":"MedicalEntity","name":"Immunoconjugates"},{"@type":"MedicalEntity","name":"Biospecimen Collection"},{"@type":"MedicalEntity","name":"Computed Tomography"},{"@type":"MedicalEntity","name":"Doxorubicin Hydrochloride"},{"@type":"MedicalEntity","name":"Filgrastim"},{"@type":"MedicalEntity","name":"Magnetic Resonance Imaging"},{"@type":"MedicalEntity","name":"Pegfilgrastim"},{"@type":"MedicalEntity","name":"Positron Emission Tomography"},{"@type":"MedicalEntity","name":"Quality-of-Life Assessment"},{"@type":"MedicalEntity","name":"Radiation Therapy"},{"@type":"MedicalEntity","name":"Vinblastine Sulfate"},{"@type":"MedicalEntity","name":"chemotherapy, nivolumab, radiation"},{"@type":"MedicalEntity","name":"chemotherapy, brentuximab vedotin, radiation"}],"trialDesign":["https://schema.org/MultiCenterTrial"]},{"@type":"Offer","availabilityEnds":"2025-04-01","availabilityStarts":"2019-08-29","hasAdultConsideration":[],"name":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","price":0,"priceCurrency":"USD","sku":"NCT03907488","validFrom":"2019-08-29","validThrough":"2025-04-01"},{"@context":"https://schema.org/","@type":"Place","address":{"@type":"PostalAddress","addressCountry":"United States","addressLocality":"San Francisco","addressRegion":"California","postalCode":"94158"},"name":"UCSF Medical Center-Mission Bay"}] </script> </main><footer class="mt-auto" role="contentinfo" data-nosnippet><div id="ucsf--footer--body"><div class="container" data-nosnippet><div class="row mb-1 d-print-none"><div class="col-12 text-center text-md-left"> We use cookies to operate our website, analyze performance, and improve your experience on our site. <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Learn more.</a> </div></div><div class="row"><div class="col-md-6 text-center text-md-left"><p class="my-0"> © The Regents of the University of California </p></div><div class="col-md-6 text-center text-md-right pt-3 pt-md-0"> <a href="https://websites.ucsf.edu/digital-accessibility" target="_blank">Accessibility</a> <a href="https://www.ucsf.edu/website-privacy-policy" target="_blank">Privacy Policy</a> <a href="https://websites.ucsf.edu/website-terms-use" target="_blank">Terms of Use</a> </div></div></div></div></footer><script>(function(){var b=document.createElement('script');b.type='text/javascript';b.async=true;b.src='//siteimproveanalytics.com/js/siteanalyze_8343.js';var a=document.getElementsByTagName('script')[0];a.parentNode.insertBefore(b,a)})();</script></body></html>